| 发明名称 |
Defective Mismatch Repair and Benefit from Bevacizumab for Colon Cancer |
| 摘要 |
Methods of testing to identify and to treat a subset of colon cancer patients exhibiting dMMR tumor tissue, who derive significant clinical benefit from the addition of bevacizumab to standard adjuvant chemotherapy. The presence of a V600E BRAF mutation is also of significance. |
| 申请公布号 |
US2014348821(A1) |
申请公布日期 |
2014.11.27 |
| 申请号 |
US201414286796 |
申请日期 |
2014.05.23 |
| 申请人 |
NSABP Foundation, Inc. |
发明人 |
Pogue-Geile Katherine Lea;Paik Soonmyung |
| 分类号 |
C07K16/22;A61K45/06;A61K39/395;C12Q1/68;G01N33/574 |
主分类号 |
C07K16/22 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method for treating a cancer patient comprising:
identifying a cancer patient with mismatch repair deficient (dMMR) tumor tissue; and administering an anti-angiogenesis agent to the patient. |
| 地址 |
Pittsburgh PA US |
